Get started
IPSEN SA EUR1IPSEN SA EUR1IPSEN SA EUR1

IPSEN SA EUR1

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

0MH6 chart

Upcoming earnings

Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪9.29 B‬EUR
Dividend yield (indicated)
1.07%
Price to earnings Ratio (TTM)
14.5
Basic EPS (TTM)
7.8EUR
Net income (FY)
‪644.40 M‬EUR
Revenue (FY)
‪3.13 B‬EUR
Shares float
‪34.73 M‬
Beta (1Y)
0.61

About IPSEN

Sector
Health Technology
CEO
David G. Loew
Headquarters
Boulogne-Billancourt
Website
ipsen.com
Employees (FY)
‪5.33 K‬
Founded
1998
ISIN
FR0010259150
FIGI
BBG000M2T534
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 0MH6 is 113.0 EUR — it has increased by 0.62% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange IPSEN SA EUR1 stocks are traded under the ticker 0MH6.
IPSEN SA EUR1 is going to release the next earnings report on Jul 24, 2024. Keep track of upcoming events with our Earnings Calendar.
0MH6 stock is 1.52% volatile and has beta coefficient of 0.61. Check out the list of the most volatile stocks — is IPSEN SA EUR1 there?
0MH6 earnings for the last quarter are 4.73 EUR per share, whereas the estimation was 4.98 EUR resulting in a −5.02% surprise. The estimated earnings for the next quarter are 5.23 EUR per share. See more details about IPSEN SA EUR1 earnings.
IPSEN SA EUR1 revenue for the last quarter amounts to ‪1.54 B‬ EUR despite the estimated figure of ‪1.53 B‬ EUR. In the next quarter revenue is expected to reach ‪1.73 B‬ EUR.
Yes, you can track IPSEN SA EUR1 financials in yearly and quarterly reports right on TradingView.
0MH6 stock has risen by 6.81% compared to the previous week, the month change is a 3.67% rise, over the last year IPSEN SA EUR1 has showed a 5.02% increase.
0MH6 net income for the last quarter is ‪449.20 M‬ EUR, while the quarter before that showed ‪195.20 M‬ EUR of net income which accounts for 130.12% change. Track more IPSEN SA EUR1 financial stats to get the full picture.
Today IPSEN SA EUR1 has the market capitalization of ‪9.34 B‬, it has increased by 4.55% over the last week.
Yes, 0MH6 dividends are paid annually. The last dividend per share was 1.20 EUR. As of today, Dividend Yield (TTM)% is 1.06%. Tracking IPSEN SA EUR1 dividends might help you take more informed decisions.
IPSEN SA EUR1 dividend yield was 1.11% in 2023, and payout ratio reached 15.40%. The year before the numbers were 1.19% and 15.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 0MH6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IPSEN SA EUR1 stock right from TradingView charts — choose your broker and connect to your account.
0MH6 reached its all-time high on Sep 12, 2018 with the price of 155.6 EUR, and its all-time low was 18.3 EUR and was reached on Aug 24, 2012.
See other stocks reaching their highest and lowest prices.
As of Apr 27, 2024, the company has ‪5.33 K‬ employees. See our rating of the largest employees — is IPSEN SA EUR1 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IPSEN SA EUR1 technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IPSEN SA EUR1 stock shows the buy signal. See more of IPSEN SA EUR1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on IPSEN SA EUR1 future price: according to them, 0MH6 price has a max estimate of 161.00 EUR and a min estimate of 110.00 EUR. Read a more detailed IPSEN SA EUR1 forecast: see what analysts think of IPSEN SA EUR1 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IPSEN SA EUR1 EBITDA is ‪1.30 B‬ EUR, and current EBITDA margin is 30.23%. See more stats in IPSEN SA EUR1 financial statements.